Oncology

Immutep Quarterly Activities Report

Thursday, January 21, 2021 - 11:03pm

Immutep is advancing strongly towards another step change in calendar year 2021, said Marc Voigt, CEO of Immutep.

Key Points: 
  • Immutep is advancing strongly towards another step change in calendar year 2021, said Marc Voigt, CEO of Immutep.
  • The proportion of patient events has advanced to ~ 68% currently and Immutep is on track to report final OS data and Overall Response Rates (ORR) by mid calendar year 2021.
  • In addition, Immutep completed recruitment of 2nd line HNSCC patients for Part C of the trial in early January 2021.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

Thursday, January 21, 2021 - 9:30pm

Retifanlimab has been granted Orphan Drug Designation by the FDA for the treatment of anal cancer, along with Priority Review.

Key Points: 
  • Retifanlimab has been granted Orphan Drug Designation by the FDA for the treatment of anal cancer, along with Priority Review.
  • The FDA grants Priority Review to medicines that may offer a major advance in treatment where none currently exists.
  • Retifanlimab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of anal cancer.
  • The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thursday, January 21, 2021 - 9:45pm

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
  • The stock options were granted on January 20, 2021 at an exercise price of $1.74 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • The options were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Gerons 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Drug Topics® and Managed Healthcare Executive® Announce Partnership with Scientia Pharmacy Advisors

Thursday, January 21, 2021 - 7:56pm

Drug Topics, a leading multimedia resource that has served the pharmacy field for more than 160 years, and Managed Healthcare Executive, a multimedia platform that provides market intelligence and solutions to C-suite executives of health plans, are pleased to announce a partnership with Scientia Pharmacy Advisors.

Key Points: 
  • Drug Topics, a leading multimedia resource that has served the pharmacy field for more than 160 years, and Managed Healthcare Executive, a multimedia platform that provides market intelligence and solutions to C-suite executives of health plans, are pleased to announce a partnership with Scientia Pharmacy Advisors.
  • We have worked with the founders of Scientia Pharmacy Advisors in several different capacities over the past decade, and we share the goal of advancing science and offering innovative health care solutions, said Brian Haug, Executive Vice-President, Healthcare of MJH Life Sciences, parent company of Drug Topics and Managed Healthcare Executive.
  • Through live and virtual formats, Scientia Pharmacy Advisors will leverage the Drug Topics and Managed Healthcare Executive industry-leading platforms in the pharmacy and payer verticals to help guide pharma partners and other industry professionals through the complex oncology pharmacy landscape.
  • Managed Healthcare Executive provides healthcare executives at health plans and provider organizations with analysis, insights, and strategies to pursue value-driven solutions.

Global Cancer Supportive Care Market Report 2020: An Evolving Discipline of Medicine that is Critical for Holistic Management of Patients

Thursday, January 21, 2021 - 5:15pm

The report also delves into some of the clinical trials challenges that are encountered in this field and provides an overview of unmet needs that exist for various SCC indications.

Key Points: 
  • The report also delves into some of the clinical trials challenges that are encountered in this field and provides an overview of unmet needs that exist for various SCC indications.
  • Supportive care in cancer is an evolving discipline of medicine that is critical for holistic management of patients with cancer.
  • What set of treatment guidelines and treatment options are used by oncologists in the 7MM for various indications within SCC?
  • What are the current unmet needs, and what steps are being taken to help address these gaps in SCC?

Global Cancer Gene Therapy Market Research during 2021-2025 | Industry Planning Analysis for the New Normal | Technavio

Thursday, January 21, 2021 - 3:26pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210121005646/en/
    Technavio has announced its latest market research report titled Global Cancer Gene Therapy Market 2021-2025 (Graphic: Business Wire)
    Worried about the impact of COVID-19 on your business?
  • The report on the cancer gene therapy market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The cancer gene therapy market analysis includes the application and geography landscape.
  • The cancer gene therapy market covers the following areas:

PICI's Best Practices for Building Oncology Studies in an EDC, Upcoming Webinar Hosted by Xtalks

Thursday, January 21, 2021 - 1:30pm

Learn why their legacy EDC system workarounds and custom functions no longer sustained their business, which motivated them to take a new approach.

Key Points: 
  • Learn why their legacy EDC system workarounds and custom functions no longer sustained their business, which motivated them to take a new approach.
  • In this webinar, the featured speakers will share how PICI decided to adopt a new EDC system that streamlines the build process for oncology trials and how they better equip their clinical programmers and data managers.
  • For more information, or to register for this event, visit PICI's Best Practices for Building Oncology Studies in an EDC.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.

Global Liver Cancer Therapeutics Market to 2025 by Cancer Type, Therapy, Equipment, Age, Factors, Route of Administration, Distribution Channel, Region, Competition, Forecast & Opportunities

Thursday, January 21, 2021 - 1:30pm

According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe.

Key Points: 
  • According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe.
  • Expensive treatments as well as high cost in research and development might hamper further development of liver cancer therapeutics market.
  • The Global Liver Cancer Therapeutics Market is segmented based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region.
  • The oral segment is anticipated to dominate the Global Liver Cancer Therapeutics Market during the forecast period as it is most preferred route of administration for chemotherapy.

Bio-Thera Solutions Announces Initiation of Phase I Clinical Trial for BAT1308, a Monoclonal Antibody Targeting PD-1

Thursday, January 21, 2021 - 1:08pm

Bio-Thera Solutions, Ltd. (SHA: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT1308, a monoclonal antibody targeting PD-1 in cancer patient volunteers.

Key Points: 
  • Bio-Thera Solutions, Ltd. (SHA: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT1308, a monoclonal antibody targeting PD-1 in cancer patient volunteers.
  • "We have multiple immune-oncology (IO) assets in our pipeline targeting tumor infiltrating regulatory T cells (Tregs).
  • The Phase 1, multicenter, open-label, dose-escalation clinical trial of BAT1308 is designed to assess the safety and tolerability of BAT1308 as a single agent.
  • This news release contains certain forward-looking statements relating to BAT1308 or the product pipelines in general of Bio-Thera Solutions.

CairnSurgical Announces First Patient Treated in Pivotal Clinical Trial of Breast Cancer Locator System

Thursday, January 21, 2021 - 1:00pm

CairnSurgical, Inc. , an innovator striving to make breast cancer surgery more precise, announced today that the first patient has been treated in its U.S. pivotal trial of the Breast Cancer Locator (BCL) System at Massachusetts General Hospital.

Key Points: 
  • CairnSurgical, Inc. , an innovator striving to make breast cancer surgery more precise, announced today that the first patient has been treated in its U.S. pivotal trial of the Breast Cancer Locator (BCL) System at Massachusetts General Hospital.
  • The Breast Cancer Locator (BCL) Study is a prospective, multicenter, 1:1 randomized, controlled pivotal trial of breast cancer excision surgery in 448 women with non-palpable invasive breast cancer or ductal carcinoma in situ (DCIS) tumors treated at up to 15 U.S. centers.
  • We developed the Breast Cancer Locator with the vision to provide improved clinical outcomes in order to reduce the positive margin rate.
  • CairnSurgicals Breast Cancer Locator System enables precise tumor localization and excision, and has been tested in both single arm and randomized clinical trials.